Common use of Publicity Review Clause in Contracts

Publicity Review. LILLY and RPI shall jointly discuss and agree, based on the principles of Section 12, on any statement to the public regarding the execution and the subject matter of this Agreement or any other aspect of this Agreement, except with respect to disclosures required by law or regulation. Within fifteen (15) days following the Effective Date, the Parties shall issue a joint press release covering the field of collaboration as well as total deal value amount to be mutually agreed to by the Parties (a copy of the press release is attached to this Agreement as Appendix D). In no event shall specific payment amounts be announced (i.e. license fee, Patent Reimbursement, Pre-clinical Reimbursement, royalties). Except with respect to [ * ] Confidential treatment requested information disclosed in the joint press release, neither Party shall (i) disclose the material terms of this Agreement, or (ii) use the name of the other Party, in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, which may not be unreasonably withheld or delayed, provided, however, that both parties shall endeavor in good faith to give the other Party a minimum of five business days to review such press release, prospectus, annual report, or other public statement; provided, further, that either Party may (i) disclose the material terms of this Agreement or (ii) use the name of the other Party in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, if such Party is advised by counsel that such disclosure is required to comply with applicable law.

Publicity Review. LILLY and RPI shall jointly discuss and agree, based on the principles of Section 12, on any statement to the public regarding the execution and the subject matter of this Agreement or any other aspect of this Agreement, except with respect to disclosures required by law or regulation. Within fifteen (15) days [ * ] following the Effective Date, the Parties shall issue a joint press release covering the field of collaboration as well as total deal value amount to be mutually agreed to by the Parties (a copy of the press release is attached to this Agreement as Appendix APPENDIX D). In no event shall specific payment amounts be announced (i.e. license fee, Patent Reimbursement, Pre-clinical Reimbursement, royalties). Except with respect to [ * ] Confidential treatment requested information disclosed in the joint press release, neither Party shall (i) disclose the material terms of this Agreement, or (ii) use the name of the other Party, in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, which may not be unreasonably withheld or delayed, provided, however, that both parties shall endeavor in good faith to give the other Party a minimum of five business days to review such press release, prospectus, annual report, or other public statement; provided, further, that either Party may (i) disclose the material terms of this Agreement or (ii) use the name of the other Party in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, if such Party is advised by counsel that such disclosure is required to comply with applicable law.

Publicity Review. LILLY and RPI shall jointly discuss and agree, based on the principles of Section 12, on any statement to the public regarding the execution and the subject matter of this Agreement or any other aspect of this Agreement, except with respect to disclosures required by law or regulation. Within fifteen (15) days [ * ] following the Effective Date, the Parties shall issue a joint press release covering the field of collaboration as well as total deal value amount to be mutually agreed to by the Parties (a copy of the press release is attached to this Agreement as Appendix D). In no event shall specific payment amounts be announced (i.e. license fee, Patent Reimbursement, Pre-clinical Reimbursement, royalties). Except with respect to [ * ] Confidential treatment requested information disclosed in the joint press release, neither Party shall (i) disclose the material terms of this Agreement, or (ii) use the name of the other Party, in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, which may not be unreasonably withheld or delayed, provided, however, that both parties shall endeavor in good faith to give the other Party a minimum of five business days to review such press release, prospectus, annual report, or other public statement; provided, further, that either Party may (i) disclose the material terms of this Agreement or (ii) use the name of the other Party in any public statement, prospectus, annual report, or press release without the prior written approval of the other Party, if such Party is advised by counsel that such disclosure is required to comply with applicable law.